Karyopharm Therapeutics Inc (KPTI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-15
$1.54-3.75%
Close 2026-09-15 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-15
Research Workspace
Put KPTI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
No standing thesis yet — not enough to read.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 86% in its worst 12-month stretch.
View RiskKaryopharm's potential myelofibrosis approval and revenue target must continue to drive growth. Revenue declined 6% year over year, and the last quarter missed expectations. KPTI trades at 0.0× price-to-sales versus a peer median of 12×. Expectations look modest compared to our view, indicating the price does not fully reflect potential. If KPTI cuts guidance on the next call, that would significantly impact the stock. Peer multiples imply a price about 47% above where it trades. This read is provisional.
Trailing returns as of 2026-09-15. KPTI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering KPTI (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for KPTI in the last 4 months.
Continue this research
Compare KPTI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| KPTI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put KPTI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Evaluate financing opportunities and strategic alternatives
Delaying debt payment raises concerns about financial stability.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $1.54
The last 12 months of price, then the range of analyst 12-month targets from today’s $1.54.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance myelofibrosis program with sNDA submission
SENTRY trial success supports myelofibrosis program advancement.
Advances: Increase U.S. XPOVIO Net Product Revenue
Potential approval and revenue target align with revenue growth objective.
Threatens: Secure Additional Capital
Balance sheet concerns may hinder securing additional capital.
